Table 1.
Clinical characteristics
| Characteristic | n (%) |
|---|---|
| Sex, male | 42 (32) |
| Sex, female | 90 (68) |
| Age at diagnosis, years, mean (range) | 52 (31-74) |
| Time from NSCLC diagnosis to LM, months (range) | 26 (0-156) |
| ECOG score at admission | |
| 0-2 | 47 (36) |
| 3-4 | 85 (64) |
| Brain metastasis | |
| With | 96 (73) |
| Without | 36 (27) |
| Brain radiotherapy before LM | |
| Local | 35 (27) |
| Whole | 19 (14) |
| Without | 80 (61) |
| Cytotoxic chemotherapy before LM | |
| With | 95 (72) |
| Without | 37 (28) |
| EGFR-TKI therapy before IP | |
| First generation | 96 (73) |
| Second generation | 29 (22) |
| Third generation | 111 (84) |
| Clinical manifestation | |
| Headache, nausea, or vomiting | 122 (92) |
| Disorders of consciousness or epilepsy | 39 (30) |
| Walking instability | 67 (51) |
| Optic, auditory, or facial nerve involvement | 85 (64) |
| Neck pain, back pain, or defecation difficulty | 14 (11) |
| Gene mutation detection | |
| EGFR 19 mutation | 46 (35) |
| EGFR 21 mutation | 64 (48) |
| EGFR 18 mutation | 9 (7) |
| EGFR 20 mutation | 6 (5) |
| Others | 7 (5) |
| The modality of LM diagnosis | |
| MRI+/cytology+ | 61 (46) |
| MRI−/cytology+ | 58 (44) |
| MRI+/cytology− | 13 (10) |
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; IP, intrathecal pemetrexed; LM, leptomeningeal metastases; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor.